



Clinical trial results:

A 6-month safety and benefit study of inhaled fluticasone propionate/salmeterol combination versus inhaled fluticasone propionate in the treatment of 6,200 pediatric subjects 4-11 years old with persistent asthma

Summary

| | |
|--------------------------|---|
| EudraCT number | 2011-001643-79 |
| Trial protocol | HU GB LV CZ LT ES AT SE BE DK NL BG IT FI SK DE |
| Global end of trial date | 03 November 2015 |

Results information

| | |
|--------------------------------|-------------|
| Result version number | v1 |
| This version publication date | 15 May 2016 |
| First version publication date | 15 May 2016 |

Trial information

Trial identification

| | |
|-----------------------|-----------|
| Sponsor protocol code | SAS115358 |
|-----------------------|-----------|

Additional study identifiers

| | |
|------------------------------------|---|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | - |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|--|
| Sponsor organisation name | GlaxoSmithKline |
| Sponsor organisation address | 980 Great West Road, Brentford, Middlesex, United Kingdom, |
| Public contact | GSK Response Center, GlaxoSmithKline, 1 866-435-7343, |
| Scientific contact | GSK Response Center, GlaxoSmithKline, 1 866-435-7343, |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|------------------|
| Analysis stage | Final |
| Date of interim/final analysis | 15 March 2016 |
| Is this the analysis of the primary completion data? | No |
| Global end of trial reached? | Yes |
| Global end of trial date | 03 November 2015 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

The primary objective was to evaluate whether the addition of a long-acting beta-adrenoceptor agonist (LABA) to an inhaled corticosteroid (ICS) (Fluticasone propionate/salmeterol combination [FSC]) therapy is non-inferior in terms of risk of serious asthma-related events (asthma-related hospitalizations, endotracheal intubations, and deaths) compared with ICS alone (Fluticasone Propionate [FP]) in pediatric subjects (age 4-11 years) with persistent asthma.

Protection of trial subjects:

Not applicable

Background therapy: -

Evidence for comparator: -

| | |
|---|------------------|
| Actual start date of recruitment | 17 November 2011 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|-------------------------|
| Country: Number of subjects enrolled | Canada: 97 |
| Country: Number of subjects enrolled | United States: 2796 |
| Country: Number of subjects enrolled | Argentina: 251 |
| Country: Number of subjects enrolled | Chile: 151 |
| Country: Number of subjects enrolled | Mexico: 38 |
| Country: Number of subjects enrolled | Peru: 220 |
| Country: Number of subjects enrolled | Austria: 9 |
| Country: Number of subjects enrolled | Belgium: 6 |
| Country: Number of subjects enrolled | Bulgaria: 252 |
| Country: Number of subjects enrolled | Croatia: 45 |
| Country: Number of subjects enrolled | Czech Republic: 24 |
| Country: Number of subjects enrolled | Germany: 52 |
| Country: Number of subjects enrolled | Hungary: 132 |
| Country: Number of subjects enrolled | Italy: 31 |
| Country: Number of subjects enrolled | Latvia: 70 |
| Country: Number of subjects enrolled | Lithuania: 15 |
| Country: Number of subjects enrolled | Poland: 299 |
| Country: Number of subjects enrolled | Romania: 8 |
| Country: Number of subjects enrolled | Russian Federation: 271 |

| | |
|--------------------------------------|------------------------|
| Country: Number of subjects enrolled | Serbia: 131 |
| Country: Number of subjects enrolled | Slovakia: 2 |
| Country: Number of subjects enrolled | Spain: 19 |
| Country: Number of subjects enrolled | Ukraine: 177 |
| Country: Number of subjects enrolled | United Kingdom: 33 |
| Country: Number of subjects enrolled | South Africa: 700 |
| Country: Number of subjects enrolled | Australia: 25 |
| Country: Number of subjects enrolled | Korea, Republic of: 99 |
| Country: Number of subjects enrolled | Malaysia: 82 |
| Country: Number of subjects enrolled | Philippines: 52 |
| Country: Number of subjects enrolled | Taiwan: 93 |
| Country: Number of subjects enrolled | Thailand: 70 |
| Worldwide total number of subjects | 6250 |
| EEA total number of subjects | 997 |

Notes:

Subjects enrolled per age group

| | |
|---|------|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 6249 |
| Adolescents (12-17 years) | 1 |
| Adults (18-64 years) | 0 |
| From 65 to 84 years | 0 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

A total of 6250 participants were enrolled and randomized to study treatments; total 6208 participants took at least one dose of study drug.

Pre-assignment

Screening details:

Participants aged between 4 to 11 years having asthma, defined by the regional asthma guidelines for at least 6 months, having history of at least one occurrence of treatment with systemic corticosteroid and with no change in asthma therapy for the last 4 weeks from first visit were enrolled for the study.

Period 1

| | |
|------------------------------|--------------------------------|
| Period 1 title | Overall Study (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator |

Arms

| | |
|------------------------------|---|
| Are arms mutually exclusive? | Yes |
| Arm title | Fluticasone propionate/salmeterol combination (FSC) |

Arm description:

Participants received one of following treatments: FSC 100/50 microgram (µg) or FSC 250/50 µg as one inhalation twice daily (BID) (approximately 12 hours apart) via Dry powder inhaler (DPI) during the 6 month treatment period. Treatment dose was based on participants' asthma control status and according to randomization. Rescue medication (albuterol/salbutamol) via metered dose inhaler (MDI) was permitted during study treatment.

| | |
|--|---|
| Arm type | Experimental |
| Investigational medicinal product name | Fluticasone Propionate 100 micrograms (µg) and salmeterol 50 µg inhalation powder |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Inhalation powder |
| Routes of administration | Inhalation use |

Dosage and administration details:

1 inhalation twice daily (morning and evening) via dry powder inhaler

| | |
|--|--|
| Investigational medicinal product name | Fluticasone Propionate 250 µg and salmeterol 50 µg inhalation powder |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Inhalation powder |
| Routes of administration | Inhalation use |

Dosage and administration details:

1 inhalation twice daily (morning and evening) via dry powder inhaler

| | |
|------------------|-----------------------------|
| Arm title | Fluticasone propionate (FP) |
|------------------|-----------------------------|

Arm description:

Participants received one of the following treatments: FP 100 µg or FP 250 µg as one inhalation BID (approximately 12 hours apart) via DPI during the 6 month treatment period. Treatment dose was based on participants' asthma control status and according to randomization. Rescue medication (albuterol/salbutamol) via MDI was permitted during study treatment.

| | |
|----------|-------------------|
| Arm type | Active comparator |
|----------|-------------------|

| | |
|--|---|
| Investigational medicinal product name | Fluticasone Propionate 100 µg inhalation powder |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Inhalation powder |
| Routes of administration | Inhalation use |

Dosage and administration details:

1 inhalation twice daily (morning and evening) via dry powder inhaler

| | |
|--|---|
| Investigational medicinal product name | Fluticasone Propionate 250 µg inhalation powder |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Inhalation powder |
| Routes of administration | Inhalation use |

Dosage and administration details:

1 inhalation twice daily (morning and evening) via dry powder inhaler

| Number of subjects in period 1^[1] | Fluticasone propionate/salmeterol combination (FSC) | Fluticasone propionate (FP) |
|---|---|-----------------------------|
| Started | 3107 | 3101 |
| Completed | 2724 | 2751 |
| Not completed | 383 | 350 |
| Consent withdrawn by subject | 245 | 226 |
| Asthma Exacerbation | 34 | 35 |
| Adverse event, non-fatal | 24 | 23 |
| Lost to follow-up | 7 | 7 |
| Lack of efficacy | 5 | 6 |
| Protocol deviation | 68 | 53 |

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: The worldwide number enrolled was calculated from the 'Randomization Population', and included participants who were randomized to but never used study treatment whereas the number of subjects reported to be in the baseline period represents the 'Intent-to-Treat Population' which included only those randomized participants who took study treatment.

Baseline characteristics

Reporting groups

| | |
|-----------------------|---|
| Reporting group title | Fluticasone propionate/salmeterol combination (FSC) |
|-----------------------|---|

Reporting group description:

Participants received one of following treatments: FSC 100/50 microgram (µg) or FSC 250/50 µg as one inhalation twice daily (BID) (approximately 12 hours apart) via Dry powder inhaler (DPI) during the 6 month treatment period. Treatment dose was based on participants' asthma control status and according to randomization. Rescue medication (albuterol/salbutamol) via metered dose inhaler (MDI) was permitted during study treatment.

| | |
|-----------------------|-----------------------------|
| Reporting group title | Fluticasone propionate (FP) |
|-----------------------|-----------------------------|

Reporting group description:

Participants received one of the following treatments: FP 100 µg or FP 250 µg as one inhalation BID (approximately 12 hours apart) via DPI during the 6 month treatment period. Treatment dose was based on participants' asthma control status and according to randomization. Rescue medication (albuterol/salbutamol) via MDI was permitted during study treatment.

| Reporting group values | Fluticasone propionate/salmeterol combination (FSC) | Fluticasone propionate (FP) | Total |
|------------------------------------|---|-----------------------------|-------|
| Number of subjects | 3107 | 3101 | 6208 |
| Age categorical Units: Subjects | | | |

| | | | |
|---|--------|-------|------|
| Age continuous | | | |
| Population: Randomization | | | |
| Units: years | | | |
| arithmetic mean | 7.6 | 7.6 | |
| standard deviation | ± 2.21 | ± 2.2 | - |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 1187 | 1227 | 2414 |
| Male | 1920 | 1874 | 3794 |
| Race, Customized | | | |
| Units: Subjects | | | |
| African American / African Heritage | 539 | 511 | 1050 |
| American Indian or Alaskan Native | 144 | 118 | 262 |
| Asian - Central / South Asian Heritage | 30 | 37 | 67 |
| Asian - East Asian Heritage | 96 | 112 | 208 |
| Japanese Heritage | 1 | 0 | 1 |
| Asian - South East Asian Heritage | 122 | 108 | 230 |
| Native Hawaiian or Other Pacific Islander | 5 | 1 | 6 |
| White - Arabic / North African Heritage | 13 | 15 | 28 |
| White - White / Caucasian / European Heritage | 1985 | 2017 | 4002 |
| Mixed Race | 167 | 180 | 347 |
| Missing | 5 | 2 | 7 |

End points

End points reporting groups

| | |
|--|---|
| Reporting group title | Fluticasone propionate/salmeterol combination (FSC) |
| Reporting group description: Participants received one of following treatments: FSC 100/50 microgram (µg) or FSC 250/50 µg as one inhalation twice daily (BID) (approximately 12 hours apart) via Dry powder inhaler (DPI) during the 6 month treatment period. Treatment dose was based on participants' asthma control status and according to randomization. Rescue medication (albuterol/salbutamol) via metered dose inhaler (MDI) was permitted during study treatment. | |
| Reporting group title | Fluticasone propionate (FP) |
| Reporting group description: Participants received one of the following treatments: FP 100 µg or FP 250 µg as one inhalation BID (approximately 12 hours apart) via DPI during the 6 month treatment period. Treatment dose was based on participants' asthma control status and according to randomization. Rescue medication (albuterol/salbutamol) via MDI was permitted during study treatment. | |

Primary: Number of participants experiencing an event in the composite safety endpoint of serious asthma outcomes (asthma-related hospitalization, asthma-related endotracheal intubation, or asthma-related death)

| | |
|--|--|
| End point title | Number of participants experiencing an event in the composite safety endpoint of serious asthma outcomes (asthma-related hospitalization, asthma-related endotracheal intubation, or asthma-related death) |
| End point description: Composite endpoint was defined as clinically relevant endpoint that is constructed from combinations of other clinically relevant endpoints of serious asthma outcomes (i.e., asthma-related hospitalization, asthma-related endotracheal intubation, or asthma-related death). Hospitalization was defined as an inpatient stay or a ≥ 24 -hour stay in an observation area in an emergency department or other equivalent facility. Time to first event in the composite endpoint of serious asthma-related outcomes over the 6-month study treatment period was analyzed using a Cox proportional hazards regression model. An estimate of absolute risk difference and its corresponding 95% confidence interval (CI) were also included. The Intent-to-Treat (ITT) Population included all participants randomized to study drug and who took study treatment. | |
| End point type | Primary |
| End point timeframe: From Day 1 up to 6 months | |

| End point values | Fluticasone propionate/sal meterol combination (FSC) | Fluticasone propionate (FP) | | |
|-----------------------------|--|-----------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 3107 ^[1] | 3101 ^[2] | | |
| Units: Participants | 27 | 21 | | |

Notes:

[1] - ITT Population

[2] - ITT Population

Statistical analyses

| | |
|---|--|
| Statistical analysis title | Statistical Analysis 1 |
| Statistical analysis description: Estimated for Hazard ratio | |
| Comparison groups | Fluticasone propionate/salmeterol combination (FSC) v Fluticasone propionate (FP) |
| Number of subjects included in analysis | 6208 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority ^[3] |
| P-value | = 0.006 |
| Method | Regression, Cox |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 1.285 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.726 |
| upper limit | 2.272 |

Notes:

[3] - The non-inferiority comparison was statistically significant if the upper bound of the two-sided 95% CI falls below 2.675, the non-inferiority margin, and the non-inferiority test one-sided p-value <0.025.

| | |
|---|--|
| Statistical analysis title | Statistical Analysis 2 |
| Statistical analysis description: Estimated for Absolute risk difference | |
| Comparison groups | Fluticasone propionate/salmeterol combination (FSC) v Fluticasone propionate (FP) |
| Number of subjects included in analysis | 6208 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Risk difference (RD) |
| Point estimate | 0.0019 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.0024 |
| upper limit | 0.0063 |

Primary: Number of participants with at least one asthma exacerbation over the 6-month study treatment period

| | |
|--|--|
| End point title | Number of participants with at least one asthma exacerbation over the 6-month study treatment period |
| End point description: Number of participants with asthma exacerbation over the 6-month study treatment period are presented. Participants from mITT population with screening childhood asthma control test (C-ACT) scores of 20 or higher, one exacerbation in the previous year, and either low-dose inhaled corticosteroid (ICS) + one or more adjunctive therapy or medium-dose ICS monotherapy or medium-dose ICS and one or more adjunctive therapy as prior asthma therapy were included for this endpoint. Time to first exacerbation analyzed using a cox proportional hazards regression model. The number of asthma exacerbations were compared between treatments using a negative binomial regression model. The modified Intent-to-Treat (mITT) Population consisted of the ITT participants with a different data cut-off for supportive analyses of the primary composite safety endpoint. | |
| End point type | Primary |

End point timeframe:
From Day 1 up to 6 months

| End point values | Fluticasone propionate/salmeterol combination (FSC) | Fluticasone propionate (FP) | | |
|-----------------------------|---|-----------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 3107 ^[4] | 3101 ^[5] | | |
| Units: Participants | 265 | 309 | | |

Notes:

[4] - mITT Population

[5] - mITT Population

Statistical analyses

| Statistical analysis title | Statistical Analysis 1 |
|---|---|
| Comparison groups | Fluticasone propionate/salmeterol combination (FSC) v Fluticasone propionate (FP) |
| Number of subjects included in analysis | 6208 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.859 |
| Method | Regression, Cox |

Secondary: Number of participants experiencing asthma-related deaths over the 6-month study treatment period

| | |
|-----------------|---|
| End point title | Number of participants experiencing asthma-related deaths over the 6-month study treatment period |
|-----------------|---|

End point description:

Number of participants experiencing asthma-related death over the 6-month study treatment period are presented.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From Day 1 up to 6 months

| End point values | Fluticasone propionate/salmeterol combination (FSC) | Fluticasone propionate (FP) | | |
|-----------------------------|---|-----------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 3107 ^[6] | 3101 ^[7] | | |
| Units: Participants | 0 | 0 | | |

Notes:

[6] - ITT Population

[7] - ITT Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants experiencing asthma-related endotracheal intubations over the 6-month study treatment period

| | |
|-----------------|---|
| End point title | Number of participants experiencing asthma-related endotracheal intubations over the 6-month study treatment period |
|-----------------|---|

End point description:

Intubation is defined as endotracheal intubation with ventilation (mechanical or by hand). The number of participants experiencing asthma-related endotracheal intubations over the 6-month study treatment period are presented.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From Day 1 up to 6 months

| End point values | Fluticasone propionate/sal meterol combination (FSC) | Fluticasone propionate (FP) | | |
|-----------------------------|--|-----------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 3107 ^[8] | 3101 ^[9] | | |
| Units: Participants | 0 | 0 | | |

Notes:

[8] - ITT Population

[9] - ITT Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants experiencing asthma-related hospitalizations over the 6-month study treatment period

| | |
|-----------------|---|
| End point title | Number of participants experiencing asthma-related hospitalizations over the 6-month study treatment period |
|-----------------|---|

End point description:

Hospitalization is defined as a ≥ 24 -hour stay as an inpatient or in an observation ward. The number of participants experiencing asthma-related hospitalizations over the 6-month study treatment period are presented.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From Day 1 up to 6 months

| End point values | Fluticasone propionate/sal meterol combination (FSC) | Fluticasone propionate (FP) | | |
|-----------------------------|--|-----------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 3107 ^[10] | 3101 ^[11] | | |
| Units: Participants | 27 | 21 | | |

Notes:

[10] - ITT Population

[11] - ITT Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants withdrawn from study treatment due to asthma exacerbation over the 6-month study treatment period

| | |
|-----------------|--|
| End point title | Number of participants withdrawn from study treatment due to asthma exacerbation over the 6-month study treatment period |
|-----------------|--|

End point description:

An exacerbation is defined as deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) for at least 3 days (up to 10 days) or a single depot corticosteroid injection. Number of participants experiencing at least one exacerbation from mITT population were included for this endpoint. The number of participants withdrawn from study treatment due to asthma exacerbation over the 6-month study treatment period are presented.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From Day 1 up to 6 months

| End point values | Fluticasone propionate/sal meterol combination (FSC) | Fluticasone propionate (FP) | | |
|-----------------------------|--|-----------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 265 ^[12] | 309 ^[13] | | |
| Units: Participants | 33 | 35 | | |

Notes:

[12] - mITT Population

[13] - mITT Population

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of rescue-free days over the 6-month study treatment period

| | |
|-----------------|--|
| End point title | Percentage of rescue-free days over the 6-month study treatment period |
|-----------------|--|

End point description:

Rescue-free days were days without use of rescue albuterol/salbutamol (other than pre-exercise treatment) over the 6-month study treatment period. The mean percentages of rescue-free days over the months 1-6 (defined as treatment days 2-182) are summarized. Number of participants over treatment days 2-182 from mITT Population were included for this endpoint.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From Day 1 up to 6 months

| End point values | Fluticasone propionate/sal meterol combination (FSC) | Fluticasone propionate (FP) | | |
|---------------------------------------|--|-----------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 3049 ^[14] | 3036 ^[15] | | |
| Units: Percentage of rescue-free days | | | | |
| arithmetic mean (standard error) | 83 (± 0.5) | 81.9 (± 0.52) | | |

Notes:

[14] - mITT Population

[15] - mITT Population

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of asthma control days over the 6-month study treatment period

| | |
|-----------------|---|
| End point title | Percentage of asthma control days over the 6-month study treatment period |
|-----------------|---|

End point description:

An asthma control day is one on which rescue albuterol/salbutamol use was recorded as 0, no night time awakenings were recorded, no asthma exacerbations were recorded, no work, school, or daycare days were missed by caregiver or participant due to asthma, coughing symptom score was ≤ 1 and wheezing symptom score was 0. The mean percentages of asthma control days over the months 1-6 (defined as treatment days 2-182) are summarized. Number of participants over treatment days 2-182 from mITT Population were included for this endpoint.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From Day 1 up to 6 months

| End point values | Fluticasone propionate/sal meterol combination (FSC) | Fluticasone propionate (FP) | | |
|--|--|-----------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 2936 ^[16] | 2935 ^[17] | | |
| Units: Percentage of asthma control days | | | | |
| arithmetic mean (standard error) | 74.8 (± 0.57) | 73.4 (± 0.58) | | |

Notes:

[16] - mITT Population

[17] - mITT Population

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of study medication until follow-up (up to 6 months).

Adverse event reporting additional description:

Due to the extensive safety database of FSC, FP, and albuterol/salbutamol, and the outcomes of interest in this study, the only non-serious AEs that were collected in this study are those that lead to study drug discontinuation.

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|--------------------|--------|
| Dictionary name | MedDRA |
| Dictionary version | 18.1 |

Reporting groups

| | |
|-----------------------|---|
| Reporting group title | Fluticasone propionate/salmeterol combination (FSC) |
|-----------------------|---|

Reporting group description:

Participants received one of following treatments: FSC 100/50 microgram (µg) or FSC 250/50 µg as one inhalation twice daily (BID) (approximately 12 hours apart) via Dry powder inhaler (DPI) during the 6 month treatment period. Treatment dose was based on participants' asthma control status and according to randomization. Rescue medication (albuterol/salbutamol) via metered dose inhaler (MDI) was permitted during study treatment.

| | |
|-----------------------|-----------------------------|
| Reporting group title | Fluticasone propionate (FP) |
|-----------------------|-----------------------------|

Reporting group description:

Participants received one of the following treatments: FP 100 µg or FP 250 µg as one inhalation BID (approximately 12 hours apart) via DPI during the 6 month treatment period. Treatment dose was based on participants' asthma control status and according to randomization. Rescue medication (albuterol/salbutamol) via MDI was permitted during study treatment.

| Serious adverse events | Fluticasone propionate/salmeterol combination (FSC) | Fluticasone propionate (FP) | |
|--|---|-----------------------------|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 56 / 3107 (1.80%) | 54 / 3101 (1.74%) | |
| number of deaths (all causes) | 0 | 0 | |
| number of deaths resulting from adverse events | | | |
| General disorders and administration site conditions | | | |
| Effusion | | | |
| subjects affected / exposed | 0 / 3107 (0.00%) | 1 / 3101 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Immune system disorders | | | |
| Anaphylactic shock | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 0 / 3107 (0.00%) | 1 / 3101 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Drug hypersensitivity | | | |
| subjects affected / exposed | 0 / 3107 (0.00%) | 1 / 3101 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypersensitivity | | | |
| subjects affected / exposed | 0 / 3107 (0.00%) | 1 / 3101 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Asthma | | | |
| subjects affected / exposed | 23 / 3107 (0.74%) | 13 / 3101 (0.42%) | |
| occurrences causally related to treatment / all | 4 / 23 | 1 / 13 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bronchial hyperreactivity | | | |
| subjects affected / exposed | 1 / 3107 (0.03%) | 0 / 3101 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dyspnoea | | | |
| subjects affected / exposed | 0 / 3107 (0.00%) | 1 / 3101 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Injury, poisoning and procedural complications | | | |
| Concussion | | | |
| subjects affected / exposed | 1 / 3107 (0.03%) | 2 / 3101 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Animal bite | | | |
| subjects affected / exposed | 1 / 3107 (0.03%) | 0 / 3101 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

| | | | |
|---|------------------|------------------|--|
| Femur fracture | | | |
| subjects affected / exposed | 0 / 3107 (0.00%) | 1 / 3101 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Forearm fracture | | | |
| subjects affected / exposed | 1 / 3107 (0.03%) | 0 / 3101 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Laceration | | | |
| subjects affected / exposed | 1 / 3107 (0.03%) | 0 / 3101 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Post procedural complication | | | |
| subjects affected / exposed | 1 / 3107 (0.03%) | 0 / 3101 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Postoperative fever | | | |
| subjects affected / exposed | 1 / 3107 (0.03%) | 0 / 3101 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Road traffic accident | | | |
| subjects affected / exposed | 1 / 3107 (0.03%) | 0 / 3101 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Shunt malfunction | | | |
| subjects affected / exposed | 1 / 3107 (0.03%) | 0 / 3101 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Skull fractured base | | | |
| subjects affected / exposed | 0 / 3107 (0.00%) | 1 / 3101 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tibia fracture | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3107 (0.03%) | 0 / 3101 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Upper limb fracture | | | |
| subjects affected / exposed | 1 / 3107 (0.03%) | 0 / 3101 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac disorders | | | |
| Arrhythmia | | | |
| subjects affected / exposed | 0 / 3107 (0.00%) | 1 / 3101 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Blood and lymphatic system disorders | | | |
| Lymphadenitis | | | |
| subjects affected / exposed | 1 / 3107 (0.03%) | 1 / 3101 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal disorders | | | |
| Abdominal pain | | | |
| subjects affected / exposed | 0 / 3107 (0.00%) | 2 / 3101 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastritis | | | |
| subjects affected / exposed | 1 / 3107 (0.03%) | 1 / 3101 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Colitis | | | |
| subjects affected / exposed | 1 / 3107 (0.03%) | 0 / 3101 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Constipation | | | |
| subjects affected / exposed | 0 / 3107 (0.00%) | 1 / 3101 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

| | | | |
|---|------------------|------------------|--|
| Enterocolitis | | | |
| subjects affected / exposed | 1 / 3107 (0.03%) | 0 / 3101 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatobiliary disorders | | | |
| Hepatitis | | | |
| subjects affected / exposed | 1 / 3107 (0.03%) | 0 / 3101 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Skin and subcutaneous tissue disorders | | | |
| Henoch-Schonlein purpura | | | |
| subjects affected / exposed | 1 / 3107 (0.03%) | 0 / 3101 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal and urinary disorders | | | |
| Haematuria | | | |
| subjects affected / exposed | 1 / 3107 (0.03%) | 0 / 3101 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nephritis | | | |
| subjects affected / exposed | 1 / 3107 (0.03%) | 0 / 3101 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urinary tract disorder | | | |
| subjects affected / exposed | 0 / 3107 (0.00%) | 1 / 3101 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Musculoskeletal and connective tissue disorders | | | |
| Synovitis | | | |
| subjects affected / exposed | 0 / 3107 (0.00%) | 1 / 3101 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infections and infestations | | | |
| Pneumonia | | | |

| | | | |
|---|-------------------|------------------|--|
| subjects affected / exposed | 11 / 3107 (0.35%) | 8 / 3101 (0.26%) | |
| occurrences causally related to treatment / all | 0 / 11 | 0 / 8 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bronchitis | | | |
| subjects affected / exposed | 3 / 3107 (0.10%) | 2 / 3101 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urinary tract infection | | | |
| subjects affected / exposed | 1 / 3107 (0.03%) | 2 / 3101 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Appendicitis | | | |
| subjects affected / exposed | 1 / 3107 (0.03%) | 1 / 3101 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastroenteritis | | | |
| subjects affected / exposed | 0 / 3107 (0.00%) | 2 / 3101 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lower respiratory tract infection | | | |
| subjects affected / exposed | 1 / 3107 (0.03%) | 1 / 3101 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pharyngotonsillitis | | | |
| subjects affected / exposed | 1 / 3107 (0.03%) | 1 / 3101 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumonia viral | | | |
| subjects affected / exposed | 1 / 3107 (0.03%) | 1 / 3101 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tonsillitis | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 3107 (0.00%) | 2 / 3101 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Viral infection | | | |
| subjects affected / exposed | 1 / 3107 (0.03%) | 1 / 3101 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Abscess limb | | | |
| subjects affected / exposed | 0 / 3107 (0.00%) | 1 / 3101 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Acute sinusitis | | | |
| subjects affected / exposed | 0 / 3107 (0.00%) | 1 / 3101 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bullous impetigo | | | |
| subjects affected / exposed | 0 / 3107 (0.00%) | 1 / 3101 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Eczema infected | | | |
| subjects affected / exposed | 0 / 3107 (0.00%) | 1 / 3101 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infectious mononucleosis | | | |
| subjects affected / exposed | 1 / 3107 (0.03%) | 0 / 3101 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Influenza | | | |
| subjects affected / exposed | 1 / 3107 (0.03%) | 0 / 3101 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Meningitis | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 3107 (0.00%) | 1 / 3101 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Peritonitis | | | |
| subjects affected / exposed | 1 / 3107 (0.03%) | 0 / 3101 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pharyngitis | | | |
| subjects affected / exposed | 0 / 3107 (0.00%) | 1 / 3101 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pharyngitis streptococcal | | | |
| subjects affected / exposed | 0 / 3107 (0.00%) | 1 / 3101 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pseudocroup | | | |
| subjects affected / exposed | 0 / 3107 (0.00%) | 1 / 3101 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 1 / 3107 (0.03%) | 0 / 3101 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Viral myositis | | | |
| subjects affected / exposed | 0 / 3107 (0.00%) | 1 / 3101 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Viral tonsillitis | | | |
| subjects affected / exposed | 1 / 3107 (0.03%) | 0 / 3101 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metabolism and nutrition disorders | | | |
| Metabolic disorder | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 3107 (0.00%) | 1 / 3101 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

Frequency threshold for reporting non-serious adverse events: 0 %

| Non-serious adverse events | Fluticasone propionate/salmeterol combination (FSC) | Fluticasone propionate (FP) | |
|---|---|-----------------------------|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 31 / 3107 (1.00%) | 39 / 3101 (1.26%) | |
| Cardiac disorders | | | |
| Palpitations | | | |
| subjects affected / exposed | 1 / 3107 (0.03%) | 1 / 3101 (0.03%) | |
| occurrences (all) | 1 | 1 | |
| Nervous system disorders | | | |
| Headache | | | |
| subjects affected / exposed | 2 / 3107 (0.06%) | 2 / 3101 (0.06%) | |
| occurrences (all) | 2 | 2 | |
| Tremor | | | |
| subjects affected / exposed | 2 / 3107 (0.06%) | 0 / 3101 (0.00%) | |
| occurrences (all) | 3 | 0 | |
| Dizziness | | | |
| subjects affected / exposed | 0 / 3107 (0.00%) | 1 / 3101 (0.03%) | |
| occurrences (all) | 0 | 1 | |
| Psychomotor hyperactivity | | | |
| subjects affected / exposed | 1 / 3107 (0.03%) | 0 / 3101 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| General disorders and administration site conditions | | | |
| Chest discomfort | | | |
| subjects affected / exposed | 0 / 3107 (0.00%) | 1 / 3101 (0.03%) | |
| occurrences (all) | 0 | 1 | |
| Eye disorders | | | |
| Eye swelling | | | |
| subjects affected / exposed | 0 / 3107 (0.00%) | 1 / 3101 (0.03%) | |
| occurrences (all) | 0 | 1 | |
| Gastrointestinal disorders | | | |

| | | | |
|---|-------------------------|-------------------------|--|
| Abdominal pain upper subjects affected / exposed occurrences (all) | 1 / 3107 (0.03%) 1 | 0 / 3101 (0.00%) 0 | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Asthma subjects affected / exposed occurrences (all) | 15 / 3107 (0.48%) 15 | 23 / 3101 (0.74%) 23 | |
| Cough subjects affected / exposed occurrences (all) | 2 / 3107 (0.06%) 2 | 2 / 3101 (0.06%) 2 | |
| Wheezing subjects affected / exposed occurrences (all) | 1 / 3107 (0.03%) 1 | 1 / 3101 (0.03%) 1 | |
| Bronchospasm subjects affected / exposed occurrences (all) | 1 / 3107 (0.03%) 1 | 0 / 3101 (0.00%) 0 | |
| Dyspnoea subjects affected / exposed occurrences (all) | 0 / 3107 (0.00%) 0 | 1 / 3101 (0.03%) 1 | |
| Nasal congestion subjects affected / exposed occurrences (all) | 1 / 3107 (0.03%) 1 | 0 / 3101 (0.00%) 0 | |
| Oropharyngeal pain subjects affected / exposed occurrences (all) | 0 / 3107 (0.00%) 0 | 1 / 3101 (0.03%) 1 | |
| Pharyngeal inflammation subjects affected / exposed occurrences (all) | 0 / 3107 (0.00%) 0 | 1 / 3101 (0.03%) 1 | |
| Rhinitis allergic subjects affected / exposed occurrences (all) | 0 / 3107 (0.00%) 0 | 1 / 3101 (0.03%) 1 | |
| Skin and subcutaneous tissue disorders | | | |
| Urticaria subjects affected / exposed occurrences (all) | 1 / 3107 (0.03%) 1 | 1 / 3101 (0.03%) 1 | |
| Eczema | | | |

| | | | |
|--|-----------------------|-----------------------|--|
| subjects affected / exposed occurrences (all) | 0 / 3107 (0.00%) 0 | 1 / 3101 (0.03%) 1 | |
| Pityriasis rosea subjects affected / exposed occurrences (all) | 0 / 3107 (0.00%) 0 | 1 / 3101 (0.03%) 1 | |
| Psychiatric disorders Insomnia subjects affected / exposed occurrences (all) | 2 / 3107 (0.06%) 2 | 0 / 3101 (0.00%) 0 | |
| Irritability subjects affected / exposed occurrences (all) | 1 / 3107 (0.03%) 1 | 1 / 3101 (0.03%) 1 | |
| Abnormal behaviour subjects affected / exposed occurrences (all) | 1 / 3107 (0.03%) 1 | 0 / 3101 (0.00%) 0 | |
| Musculoskeletal and connective tissue disorders Juvenile idiopathic arthritis subjects affected / exposed occurrences (all) | 0 / 3107 (0.00%) 0 | 1 / 3101 (0.03%) 1 | |
| Infections and infestations Pneumonia subjects affected / exposed occurrences (all) | 1 / 3107 (0.03%) 1 | 1 / 3101 (0.03%) 1 | |
| Upper respiratory tract infection subjects affected / exposed occurrences (all) | 2 / 3107 (0.06%) 2 | 0 / 3101 (0.00%) 0 | |
| Bronchitis subjects affected / exposed occurrences (all) | 0 / 3107 (0.00%) 0 | 1 / 3101 (0.03%) 1 | |
| Lower respiratory tract infection subjects affected / exposed occurrences (all) | 1 / 3107 (0.03%) 1 | 0 / 3101 (0.00%) 0 | |
| Nasopharyngitis subjects affected / exposed occurrences (all) | 0 / 3107 (0.00%) 0 | 1 / 3101 (0.03%) 1 | |
| Pharyngitis streptococcal | | | |

| | | | |
|-----------------------------|------------------|------------------|--|
| subjects affected / exposed | 1 / 3107 (0.03%) | 0 / 3101 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Rhinitis | | | |
| subjects affected / exposed | 1 / 3107 (0.03%) | 0 / 3101 (0.00%) | |
| occurrences (all) | 1 | 0 | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported